PHAXIAM Therapeutics Future Growth
Future criteria checks 4/6
PHAXIAM Therapeutics is forecast to grow earnings and revenue by 144.6% and 10.3% per annum respectively while EPS is expected to grow by 82.5% per annum.
Key information
144.6%
Earnings growth rate
82.5%
EPS growth rate
Biotechs earnings growth | 19.6% |
Revenue growth rate | 10.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 2 | 1 | 1 | 1 | 2 |
12/31/2024 | 1 | -1 | 0 | 0 | 2 |
12/31/2023 | 1 | -23 | -25 | -24 | N/A |
9/30/2023 | 6 | -12 | N/A | N/A | N/A |
6/30/2023 | 6 | -11 | -23 | -23 | N/A |
3/31/2023 | 6 | 6 | N/A | N/A | N/A |
12/31/2022 | 7 | 0 | -32 | -32 | N/A |
9/30/2022 | 2 | -18 | N/A | N/A | N/A |
6/30/2022 | 3 | -27 | -45 | -45 | N/A |
3/31/2022 | 3 | -54 | N/A | N/A | N/A |
12/31/2021 | 4 | -54 | -57 | -57 | N/A |
9/30/2021 | 4 | -61 | N/A | N/A | N/A |
6/30/2021 | 4 | -66 | -55 | -55 | N/A |
3/31/2021 | 4 | -68 | N/A | N/A | N/A |
12/31/2020 | 4 | -73 | -53 | -52 | N/A |
9/30/2020 | 4 | -73 | N/A | N/A | N/A |
6/30/2020 | 4 | -68 | -52 | -49 | N/A |
3/31/2020 | 5 | -69 | N/A | N/A | N/A |
12/31/2019 | 5 | -63 | -63 | -43 | N/A |
9/30/2019 | 6 | -52 | -69 | -38 | N/A |
6/30/2019 | 5 | -49 | -73 | -52 | N/A |
3/31/2019 | 4 | -38 | N/A | N/A | N/A |
12/31/2018 | 4 | -38 | -53 | -48 | N/A |
9/30/2018 | 3 | -42 | N/A | N/A | N/A |
6/30/2018 | 4 | -38 | -33 | -31 | N/A |
3/31/2018 | 3 | -39 | N/A | N/A | N/A |
12/31/2017 | 3 | -34 | -26 | -25 | N/A |
9/30/2017 | 4 | -27 | N/A | N/A | N/A |
6/30/2017 | 4 | -26 | N/A | -23 | N/A |
3/31/2017 | 5 | -24 | N/A | N/A | N/A |
12/31/2016 | 4 | -22 | N/A | -18 | N/A |
9/30/2016 | 4 | -20 | N/A | -17 | N/A |
6/30/2016 | 4 | -19 | N/A | -17 | N/A |
3/31/2016 | 3 | -16 | N/A | N/A | N/A |
12/31/2015 | 3 | -15 | N/A | -15 | N/A |
9/30/2015 | 3 | -14 | N/A | -12 | N/A |
6/30/2015 | 2 | -12 | N/A | -10 | N/A |
3/31/2015 | 2 | -11 | N/A | -9 | N/A |
12/31/2014 | 2 | -9 | N/A | -7 | N/A |
9/30/2014 | 2 | -8 | N/A | -7 | N/A |
6/30/2014 | 2 | -7 | N/A | -6 | N/A |
3/31/2014 | 2 | -8 | N/A | -6 | N/A |
12/31/2013 | 2 | -8 | N/A | -6 | N/A |
9/30/2013 | 4 | -5 | N/A | N/A | N/A |
6/30/2013 | 6 | -2 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0QSS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: 0QSS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 0QSS is expected to become profitable in the next 3 years.
Revenue vs Market: 0QSS's revenue (10.3% per year) is forecast to grow faster than the UK market (3.4% per year).
High Growth Revenue: 0QSS's revenue (10.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0QSS's Return on Equity is forecast to be high in 3 years time